Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patients with chronic hepatitis C virus (HCV) genotype 1b infection in real world. Methods: We enrolled 278 patients (184 treatment-naïve patients) from five hospitals in Daegu and Gyeongsangbuk-do. We evaluated the rates of rapid virologic response (RVR), end-of-treatment response (ETR), and SVR at 12 weeks after completion of treatment (SVR12). Furthermore, we investigated the rate of adverse events and predictive factors of SVR12 failure. Results: The mean age of patients was 59.5 ± 10.6 years, and 140 patients (50.2%) were men. Seventy-seven patients had cirrhosis. Baseline information regarding nonstructural protein 5A (NS5A) sequences was available in 268 patients. Six patients presented with pretreatment NS5A resistance-associated variants. The RVR and the ETR rates were 96.6% (258/267) and 95.2% (223/232), respectively. The overall SVR12 rate was 91.6% (197/215). Adverse events occurred in 17 patients (7.9%). Six patients discontinued treatment because of liver enzyme elevation (n = 4) and severe nausea (n = 2). Among these, four achieved SVR12. Other adverse events observed were fatigue, headache, diarrhea, dizziness, loss of appetite, skin rash, and dyspnea. Univariate analysis did not show significant predictive factors of SVR12 failure. Conclusions: DCV and ASV combination therapy showed high rates of RVR, ETR, and SVR12 in chronic HCV genotype 1b-infected patients in real world and was well tolerated without serious adverse events.
Abstract
Background/Aims: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patients with chronic hepatitis C virus (HCV) genotype 1b infection in real world. Methods: We enrolled 278 patients (184 treatment-naïve patients) from five hospitals in Daegu and Gyeongsangbuk-do. We evaluated the rates of rapid virologic response (RVR), end-of-treatment response (ETR), and SVR at 12 weeks after completion of treatment (SVR12). Furthermore, we investigated the rate of adverse events and predictive factors of SVR12 failure. Results: The mean age of patients was 59.5 ± 10.6 years, and 140 patients (50.2%) were men. Seventy-seven patients had cirrhosis. Baseline information regarding nonstructural protein 5A (NS5A) sequences was available in 268 patients. Six patients presented with pretreatment NS5A resistance-associated variants. The RVR and the ETR rates were 96.6% (258/267) and 95.2% (223/232), respectively. The overall SVR12 rate was 91.6% (197/215). Adverse events occurred in 17 patients (7.9%). Six patients discontinued treatment because of liver enzyme elevation (n = 4) and severe nausea (n = 2). Among these, four achieved SVR12. Other adverse events observed were fatigue, headache, diarrhea, dizziness, loss of appetite, skin rash, and dyspnea. Univariate analysis did not show significant predictive factors of SVR12 failure. Conclusions: DCV and ASV combination therapy showed high rates of RVR, ETR, and SVR12 in chronic HCV genotype 1b-infected patients in real world and was well tolerated without serious adverse events.
참고문헌 (22)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C : a randomised trial", Lancet, 358, pp.958~965 (2001)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Fried MW, "Once-daily simeprevir(TMC435)with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C : the randomized PILLAR study", Hepatology, 58, pp.1918~1929 (2013)
- Kumada H, "Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan", J Hepatol, 56, pp.78~84 (2012)
- Hayashi N, "Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection : a randomized phase II study", J Gastroenterol, 50, pp.238~248 (2015)
- Chayama K, "Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders", Hepatology, 55, pp.742~748 (2012)
- Suzuki Y, "Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options", J Hepatol, 58, pp.655~662 (2013)
- "All-oral combination of daclatasvir plus asunaprevir in interferon-ineligible naive/intolerant and nonresponder Japanese patients chronically infected with HCV genotype 1b: results from a phase 3 trial: the 64th Annual Meeting of the American Association for the Study of Liver Disease" (2013)[URL]
- Kumada H, "Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection", Hepatology, 59, pp.2083~2091 (2014)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- 조병욱, "Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study", Clinical and Molecular Hepatology, 23(1), pp.51~56 (2017), 대한간학회[DOI]
- Kao JH, "All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus(HCV)genotype 1b infection : a sub-analysis in Asian patients from the HALLMARK DUAL study", Liver Int, 36, pp.1433~1441 (2016)
- Tamori A, "Outcomes for cirrhotic patients with hepatitis C virus 1b treated with asunaprevir and daclatasvir combination", Ann Hepatol, 16, pp.734~741 (2017)
- Tada T, "Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response", J Gastroenterol Hepatol, 32, pp.1982~1988 (2017)
- Mandorfer M, "Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension", J Hepatol, 65, pp.692~699 (2016)
- Fujii H, "Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions", World J Hepatol, 9, pp.1064~1072 (2017)
- Manns M, "All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b : a multinational, phase 3, multicohort study", Lancet, 384, pp.1597~1605 (2014)
- Wang HL, "Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b : systematic review and meta-analysis", J Gastroenterol Hepatol, 32, pp.45~52 (2017)
- Regan CP, "Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys", Hepatology, 64, pp.1430~1441 (2016)
- Ishigami M, "Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection : real-world data", J Gastroenterol Hepatol, 32, pp.1879~1886 (2017)
- Sezaki H, "The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings", Liver Int, 37, pp.1325~1333 (2017)
- Fujii Y, "Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir", Hepatology, 61, pp.400~401 (2015)